Laxiriva

Sodium hydrogen carbonate, potassium chloride, sodium chloride, and macrogol 3350, the active ingredients in Laxiriva, are an osmotic laxative presented as an oral solution for adult use. It helps relieve occasional constipation by increasing water content in the intestines and promotes regular bowel movements.

GNH USA supplies Laxiriva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Laxiriva is an osmotic laxative used to manage constipation by increasing intestinal water content.

Occasional constipation: Relieves infrequent constipation by drawing water into the bowel to soften stool. Functional constipation: Improves regularity in patients with chronic functional bowel patterns. Opioid‑induced constipation: Counteracts reduced motility caused by opioid therapy through osmotic action.

Laxiriva may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal cramping - Bloating - Nausea - Flatulence - Mild diarrhea - Mild electrolyte imbalance

Serious or Rare Side Effects: - Severe dehydration - Significant electrolyte disturbances (e.g., hypernatremia, hyperkalemia) - Allergic reactions such as rash or angioedema - Severe abdominal pain - Rectal bleeding - Rare colonic perforation

When using Laxiriva, consider the following precautions to ensure safe and effective therapy.

Assess hydration status: Verify patient is adequately hydrated before initiating therapy. Review electrolyte balance: Monitor serum electrolytes, especially potassium and sodium, during prolonged use. Avoid in intestinal obstruction: Do not use if there is known bowel blockage or perforation. Use cautiously in renal impairment: Adjust use in patients with reduced kidney function. Do not exceed recommended dose: Follow prescriber instructions to prevent over‑use. Store at ambient temperature: Keep the solution in its original container, protect from moisture and direct sunlight.

Laxiriva can interact with other medicines; awareness of key interactions helps prevent complications.

Major Interactions (Avoid): - Concurrent high‑dose potassium supplements: May cause dangerous hyperkalemia. - Co‑administration with other osmotic laxatives: Increases risk of severe electrolyte imbalance.

Moderate Interactions (Monitor Closely): - Diuretics: May amplify electrolyte losses; monitor levels. - ACE inhibitors or ARBs: Potential additive effect on potassium; check serum potassium. - Antacids containing sodium: Can increase sodium load; observe fluid balance.